Court Closes Book on Overtime Cases

April 2011
Pharmaceutical Representative;Apr2011, Vol. 41 Issue 4, p9
The article reports on the decline from the Supreme Court to conduct a review on the lower court decisions on the overtime payments to sales representatives at Novartis AG and Merck & Co. Inc. in the U.S.


Related Articles

  • Novartis inks Merck purchase.  // Chemical Market Reporter;07/14/97, Vol. 252 Issue 2, p7 

    Discloses that Novartis has closed a deal to acquire Merck & Co.'s crop protection unit. Terms under transaction.

  • Wins.  // Travel Daily;11/24/2016, p6 

    The article offers information on several winners for Travel Management Companies (TMC) listed by the journal "Travel Daily" including pharmaceutical firms Merck, Novartis, and Astra Zeneca.

  • Company News Roundup. Houlton, Sarah // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p20 

    Reports developments of several pharmaceutical industry as of September 2003 in the U.S. Approval of Crestor, a cholesterol-lowering agent from AstraZeneca Inc. by the U.S. Food and Drug Administration; Commercialization of cetuximab, an anticancer agent from Merck; Details on the half-year...

  • LATE-STAGE STANDOUTS. Iskowitz, Marc // Medical Marketing & Media;Dec2012, Vol. 47 Issue 12, p47 

    The article offers information on several therapies related to cardiovascular, infectious disease, metabolic, rheumatology and oncology including the anacetrapib from Merck & Co. Inc., the relaxin from Novartis AG, and sofosbuvir/GS-7977 from Gilead Sciences Inc.

  • product showcase.  // Pharmacy Today;Dec2007, Vol. 13 Issue 12, p15 

    The article evaluates various pharmaceutical products including Voltaren Gel from Novartis AG, Lipofen fenofibrate capsule from ProEthic Pharmaceuticals Inc. and Merck's Januvia therapy from Merck & Co. Inc.

  • Merck crops a division.  // Business News New Jersey;05/19/97, Vol. 10 Issue 16, p3 

    Reports on the announcement by Merck Incorporated of the sale of its crop-protection division, to Novartis for $910 million. Details on Novartis; Details on the operations at Merck.

  • Novartis buys Merck's pesticides business. Wood, Andrew // Chemical Week;5/21/1997, Vol. 159 Issue 20, p7 

    Provides information on the acquisition of Novartis company of the crop protection business of Merck and Company. How Merck will supply the products to Novartis under long-term agreement; Merck's product line; Focus of Merck's agrochemical business; How the Merck business will complement...

  • Brand Watch. Frederick, James; West, Diane // Drug Store News;9/24/2001, Vol. 23 Issue 14, p31 

    Presents news on the pharmaceutical industry as of September 24, 2001. Merck & Company's gain in Bayer Pharmaceuticals' voluntary market withdrawal of its top-selling drug Baycol; Why GlaxoSmithKline changed the container labeling for its antiepileptic drug Lamictal tablets; Approval received...

  • INFECTIONS & INFESTATIONS: 10F Viral infections.  // MPR - Pharmacist's Edition;Fall2011, Vol. 5 Issue 3, p185 

    The article offers information on several drugs for viral infections. It states that Epivir-HBV from GlaxoSmithKline is classified as a nucleoside analogue. It relates that Famvir from Novartis AG is indicated for treatment of acute herpes zoster. It also mentions that Intron A from Merck & Co....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics